C. Activité-métabolique-de, test de sécrétion d'un antigène vaccinal par le système de sécrétion de type III, p.69

A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward et al., Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011.
DOI : 10.3322/caac.20107

J. Kirkwood, L. Butterfield, A. Tarhini, H. Zarour, P. Kalinski et al., Immunotherapy of cancer in 2012, CA: A Cancer Journal for Clinicians, vol.102, issue.suppl 18, pp.309-344, 2012.
DOI : 10.3322/caac.20132

W. Coley, The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc. R. Soc. Med, vol.3, pp.1-48, 1910.

M. Cheever and C. Higano, PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine, Clinical Cancer Research, vol.17, issue.11, pp.3520-3526, 2011.
DOI : 10.1158/1078-0432.CCR-10-3126

P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small et al., Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, New England Journal of Medicine, vol.363, issue.5, pp.411-433, 2010.
DOI : 10.1056/NEJMoa1001294

R. Schreiber, L. Old, and M. Smyth, Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion, Science, vol.331, issue.6024, pp.1565-70, 2011.
DOI : 10.1126/science.1203486

I. Mellman, G. Coukos, and G. Dranoff, Cancer immunotherapy comes of age, Nature, vol.9, issue.7378, pp.480-489, 2011.
DOI : 10.1038/nature10673

J. Banchereau and R. Steinman, Dendritic cells and the control of immunity, Nature, vol.392, issue.6673, pp.245-52, 1998.
DOI : 10.1038/32588

J. Banchereau and A. Palucka, Dendritic cells as therapeutic vaccines against cancer, Nature Reviews Immunology, vol.10, issue.4, pp.296-306, 2005.
DOI : 10.1007/s00262-003-0429-0

R. Steinman and J. Banchereau, Taking dendritic cells into medicine. Nature, Sep, vol.27449, issue.7161, pp.419-445, 2007.

K. Liu and M. Nussenzweig, Origin and development of dendritic cells, Immunological Reviews, vol.17, issue.1, pp.45-54, 2010.
DOI : 10.1111/j.0105-2896.2009.00879.x

Y. Liu, IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell Precursors, Annual Review of Immunology, vol.23, issue.1, pp.275-306, 2005.
DOI : 10.1146/annurev.immunol.23.021704.115633

K. Palucka and J. Banchereau, Cancer immunotherapy via dendritic cells, Nature Reviews Cancer, vol.29, issue.4, pp.265-77
DOI : 10.1038/nrc3258

B. Lemaitre, E. Nicolas, L. Michaut, J. Reichhart, and J. Hoffmann, The Dorsoventral Regulatory Gene Cassette sp??tzle/Toll/cactus Controls the Potent Antifungal Response in Drosophila Adults, Cell, vol.86, issue.6, pp.973-83, 1996.
DOI : 10.1016/S0092-8674(00)80172-5

S. Akira and K. Takeda, Toll-like receptor signalling, Nature Reviews Immunology, vol.303, issue.7, 2004.
DOI : 10.1038/nri1391

R. Medzhitov, . Toll-like, . Receptors, . Innate, and . Immunity, Toll-like receptors and innate immunity, Nature Reviews Immunology, vol.274, issue.2, pp.135-180, 2001.
DOI : 10.1038/35100529

A. Iwasaki and R. Medzhitov, Toll-like receptor control of the adaptive immune responses, Nature Immunology, vol.169, issue.10, pp.987-95, 2004.
DOI : 10.1126/science.1076071

S. Seong and P. Matzinger, Opinion: Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, Nature Reviews Immunology, vol.29, issue.6, pp.469-78, 2004.
DOI : 10.1126/science.285.5430.1058

C. Reis-e-sousa, Dendritic cells in a mature age, Nature Reviews Immunology, vol.202, issue.6, pp.476-83, 2006.
DOI : 10.1038/nri1845

H. Ueno, E. Klechevsky, N. Schmitt, L. Ni, A. Flamar et al., Targeting human dendritic cell subsets for improved vaccines, Seminars in Immunology, vol.23, issue.1, pp.21-28, 2011.
DOI : 10.1016/j.smim.2011.01.004

E. Trombetta and I. Mellman, CELL BIOLOGY OF ANTIGEN PROCESSING IN VITRO AND IN VIVO, Annual Review of Immunology, vol.23, issue.1, pp.975-1028, 2005.
DOI : 10.1146/annurev.immunol.22.012703.104538

O. Joffre, E. Segura, A. Savina, and S. Amigorena, Cross-presentation by dendritic cells, Nature Reviews Immunology, vol.195, issue.8, pp.557-69, 2012.
DOI : 10.1038/nri3254

O. Shea, J. Paul, and W. , Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells, Science. Feb, vol.26327, issue.5969, pp.1098-102, 2010.

P. Muranski and N. Restifo, Essentials of Th17 cell commitment and plasticity, Blood, vol.121, issue.13, 2013.
DOI : 10.1182/blood-2012-09-378653

L. Steinman, A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell???mediated tissue damage, Nature Medicine, vol.59, issue.2, pp.139-184, 2007.
DOI : 10.1038/nm1551

W. Zou and N. Restifo, TH17 cells in tumour immunity and immunotherapy, Nature Reviews Immunology, vol.8, issue.4, pp.248-56, 2010.
DOI : 10.1038/nri2742

N. Fazilleau, L. Mark, L. Mcheyzer-williams, and M. Mcheyzer-williams, Follicular Helper T Cells: Lineage and Location, Immunity, vol.30, issue.3, pp.324-359, 2009.
DOI : 10.1016/j.immuni.2009.03.003

C. Laurent, N. Fazilleau, and P. Brousset, A novel subset of T-helper cells: follicular T-helper cells and their markers, Haematologica, vol.95, issue.3, pp.356-364, 2010.
DOI : 10.3324/haematol.2009.019133

R. Nurieva, Y. Chung, D. Hwang, X. Yang, H. Kang et al., Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity, Jul, vol.1829, issue.1, pp.138-187, 2008.

P. Savage, S. Malchow, and D. Leventhal, Basic principles of tumor-associated regulatory T cell biology, Trends in Immunology, vol.34, issue.1, pp.33-40
DOI : 10.1016/j.it.2012.08.005

M. Barry and R. Bleackley, Cytotoxic T lymphocytes: all roads lead to death, Nat. Rev. Immunol, vol.2, issue.6, pp.401-410, 2002.

L. Chen and D. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol, 2013.

P. Sharma, K. Wagner, J. Wolchok, and J. Allison, Novel cancer immunotherapy agents with survival benefit: recent successes and next steps, Nature Reviews Cancer, vol.208, issue.11, 2011.
DOI : 10.1038/nrc3153

L. Zitvogel and G. Kroemer, Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology, pp.1223-1228, 2012.

F. Hodi, O. Day, S. Mcdermott, D. Weber, R. Sosman et al., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, 2010.
DOI : 10.1056/NEJMoa1003466

L. Buonaguro, A. Petrizzo, M. Tornesello, and F. Buonaguro, Translating tumor antigens into cancer vaccines. Clin. Vaccine Immunol, pp.23-34, 2011.
DOI : 10.1128/cvi.00286-10

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019775

P. Van-der-bruggen, C. Traversari, P. Chomez, C. Lurquin, D. Plaen et al., A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, vol.254, issue.5038, pp.1643-1650, 1991.
DOI : 10.1126/science.1840703

L. Novellino, C. Castelli, and G. Parmiani, A listing of human tumor antigens recognized by T cells: March 2004 update, Cancer Immunology, Immunotherapy, vol.29, issue.3, pp.187-207, 2004.
DOI : 10.1007/s00262-004-0560-6

G. Parmiani, D. Filippo, A. Novellino, L. Castelli, and C. , Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials, The Journal of Immunology, vol.178, issue.4, pp.1975-1984, 2007.
DOI : 10.4049/jimmunol.178.4.1975

M. Cheever, J. Allison, A. Ferris, O. Finn, B. Hastings et al., The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research, Clinical Cancer Research, vol.15, issue.17, pp.5323-5360, 2009.
DOI : 10.1158/1078-0432.CCR-09-0737

P. Srivastava and R. Amato, Heat shock proteins: the ???Swiss Army Knife??? vaccines against cancers and infectious agents, Vaccine, vol.19, issue.17-19, pp.17-192590, 2001.
DOI : 10.1016/S0264-410X(00)00492-8

A. Asea, M. Rehli, E. Kabingu, J. Boch, O. Bare et al., Novel Signal Transduction Pathway Utilized by Extracellular HSP70. ROLE OF Toll-LIKE RECEPTOR (TLR) 2 AND TLR4, Journal of Biological Chemistry, vol.277, issue.17, pp.15028-15062, 2002.
DOI : 10.1074/jbc.M200497200

P. Tacken, I. De-vries, R. Torensma, and C. Figdor, Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting, Nature Reviews Immunology, vol.14, issue.10, pp.790-802, 2007.
DOI : 10.1038/nri2173

D. Fioretti, S. Iurescia, and M. Rinaldi, Recent Advances in Design of Immunogenic and Effective Naked DNA Vaccines Against Cancer, Recent Patents on Anti-Cancer Drug Discovery, vol.9, issue.1, 2013.
DOI : 10.2174/1574891X113089990037

R. Anderson and J. Schneider, Plasmid DNA and viral vector-based vaccines for the treatment of cancer, Vaccine, vol.25, issue.2, pp.24-34, 2007.
DOI : 10.1016/j.vaccine.2007.05.030

G. Kroemer, L. Zitvogel, and L. Galluzzi, Victories and deceptions in tumor immunology, OncoImmunology, vol.40, issue.1, p.23687, 2013.
DOI : 10.4161/onci.20931

R. Cawood, T. Hills, S. Wong, A. Alamoudi, S. Beadle et al., Recombinant viral vaccines for cancer, Trends in Molecular Medicine, vol.18, issue.9, pp.564-74, 2012.
DOI : 10.1016/j.molmed.2012.07.007

R. Madan, M. Bilusic, C. Heery, J. Schlom, and J. Gulley, Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines, Seminars in Oncology, vol.39, issue.3, pp.296-304, 2012.
DOI : 10.1053/j.seminoncol.2012.02.010

N. Forbes, Engineering the perfect (bacterial) cancer therapy, Nature Reviews Cancer, vol.42, issue.11, pp.785-94, 2010.
DOI : 10.1038/nrc2934

L. Gouellec, A. Chauchet, X. Polack, B. Buffat, L. Toussaint et al., Bacterial vectors for active immunotherapy reach clinical and industrial stages. Hum Vaccin Immunother, pp.1454-1462, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00813376

P. Hu, R. Tuma-warrino, M. Bryan, K. Mitchell, D. Higgins et al., Escherichia coli expressing recombinant antigen and listeriolysin O stimulate class Irestricted CD8+ T cells following uptake by human APC, J. Immunol. Feb, vol.1172, issue.3, pp.1595-601, 2004.

P. Guirnalda, L. Wood, and Y. Paterson, Listeria monocytogenes and Its Products as Agents for Cancer Immunotherapy, Adv. Immunol, vol.113, pp.81-118, 2012.
DOI : 10.1016/B978-0-12-394590-7.00004-X

H. Rüssmann, H. Shams, F. Poblete, Y. Fu, J. Galán et al., Delivery of epitopes by the Salmonella type III secretion system for vaccine development, Science, vol.281, issue.5376, pp.565-573, 1998.

W. Hegazy, X. Xu, L. Metelitsa, and M. Hensel, Evaluation of Salmonella enterica Type III Secretion System Effector Proteins as Carriers for Heterologous Vaccine Antigens, Infection and Immunity, vol.80, issue.3, pp.1193-202, 2012.
DOI : 10.1128/IAI.06056-11

V. Shahabi, P. Maciag, S. Rivera, and A. Wallecha, Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment, Bioengineered Bugs, vol.57, issue.4, pp.235-278, 2010.
DOI : 10.1158/0008-5472.CAN-08-4855

G. Cornelis, The type III secretion injectisome, Nature Reviews Microbiology, vol.103, issue.11, pp.811-836, 2006.
DOI : 10.1038/nrmicro1526

J. Galán and H. Wolf-watz, Protein delivery into eukaryotic cells by type III secretion machines, Nature, vol.281, issue.7119, pp.567-73, 2006.
DOI : 10.1038/nature05272

C. Hueck, Type III protein secretion systems in bacterial pathogens of animals and plants, Microbiol. Mol. Biol. Rev, vol.62, issue.2, pp.379-433, 1998.

D. Frank and B. Iglewski, Cloning and sequence analysis of a trans-regulatory locus required for exoenzyme S synthesis in Pseudomonas aeruginosa., Journal of Bacteriology, vol.173, issue.20, 1991.
DOI : 10.1128/jb.173.20.6460-6468.1991

E. Frithz-lindsten, Y. Du, R. Rosqvist, and A. Forsberg, Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments, Mol. Microbiol, 1997.

O. Epaulard, B. Toussaint, L. Quenee, M. Derouazi, N. Bosco et al., Anti-tumor Immunotherapy via Antigen Delivery from a Live Attenuated Genetically Engineered Pseudomonas aeruginosa Type III Secretion System-Based Vector, Molecular Therapy, vol.14, issue.5, 2006.
DOI : 10.1016/j.ymthe.2006.06.011

URL : https://hal.archives-ouvertes.fr/inserm-00144349

R. Vance, A. Rietsch, and J. Mekalanos, Role of the Type III Secreted Exoenzymes S, T, and Y in Systemic Spread of Pseudomonas aeruginosa PAO1 In Vivo, Infection and Immunity, vol.73, issue.3, 2005.
DOI : 10.1128/IAI.73.3.1706-1713.2005

D. Dacheux, J. Goure, J. Chabert, Y. Usson, and I. Attree, Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages, Molecular Microbiology, vol.95, issue.954-956, pp.76-85, 2001.
DOI : 10.1046/j.1365-2958.2001.02368.x

URL : https://hal.archives-ouvertes.fr/hal-00192534

D. Dacheux, I. Attree, C. Schneider, and B. Toussaint, Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system, Infect. Immun, vol.67, issue.11, pp.6164-6171, 1999.

D. Dacheux, B. Toussaint, M. Richard, G. Brochier, J. Croize et al., Pseudomonas aeruginosa Cystic Fibrosis Isolates Induce Rapid, Type III Secretion-Dependent, but ExoU-Independent, Oncosis of Macrophages and Polymorphonuclear Neutrophils, Infection and Immunity, vol.68, issue.5, pp.2916-2940, 2000.
DOI : 10.1128/IAI.68.5.2916-2924.2000

A. Goodman, B. Kulasekara, A. Rietsch, D. Boyd, R. Smith et al., A Signaling Network Reciprocally Regulates Genes Associated with Acute Infection and Chronic Persistence in Pseudomonas aeruginosa, Developmental Cell, vol.7, issue.5, pp.745-54, 2004.
DOI : 10.1016/j.devcel.2004.08.020

A. Hovey and D. Frank, Analyses of the DNA-binding and transcriptional activation properties of ExsA, the transcriptional activator of the Pseudomonas aeruginosa exoenzyme S regulon., Journal of Bacteriology, vol.177, issue.15, pp.4427-4463, 1995.
DOI : 10.1128/jb.177.15.4427-4436.1995

L. Quénée, D. Lamotte, and B. Polack, Combined sacB-based negative selection and cre-lox antibiotic marker recycling for efficient gene deletion in Pseudomonas aeruginosa, BioTechniques, vol.38, issue.1, pp.63-70, 2005.
DOI : 10.2144/05381ST01

O. Epaulard, M. Derouazi, C. Margerit, R. Marlu, D. Filopon et al., Optimization of a Type III Secretion System-Based Pseudomonas aeruginosa Live Vector for Antigen Delivery, Clinical and Vaccine Immunology, vol.15, issue.2, pp.308-321, 2008.
DOI : 10.1128/CVI.00278-07

URL : https://hal.archives-ouvertes.fr/hal-00381893

M. Derouazi, Y. Wang, R. Marlu, O. Epaulard, J. Mayol et al., Optimal epitope composition after antigen screening using a live bacterial delivery vector, Bioengineered Bugs, vol.47, issue.1, pp.51-60, 2010.
DOI : 10.1007/s002620050015

URL : https://hal.archives-ouvertes.fr/hal-00813353

Y. Wang, A. Gouëllec, H. Chaker, H. Asrih, B. Polack et al., Optimization of Antitumor Immunotherapy Mediated by Type III Secretion System-based Live Attenuated Bacterial Vectors, Journal of Immunotherapy, vol.35, issue.3, pp.223-257
DOI : 10.1097/CJI.0b013e31824747e5

URL : https://hal.archives-ouvertes.fr/hal-00849581

J. Alexander, J. Sidney, S. Southwood, J. Ruppert, C. Oseroff et al., Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides, Immunity, vol.1, issue.9, pp.751-61, 1994.
DOI : 10.1016/S1074-7613(94)80017-0

S. Wollowitz, Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma, Semin. Hematol, 2001.

T. Dubensky, . Jr, J. Skoble, P. Lauer, and D. Brockstedt, Killed but metabolically active vaccines, Current Opinion in Biotechnology, vol.23, issue.6, pp.917-940, 2012.
DOI : 10.1016/j.copbio.2012.04.005

D. Brockstedt, K. Bahjat, M. Giedlin, W. Liu, M. Leong et al., Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity, Nature Medicine, vol.166, issue.8, pp.853-60, 2005.
DOI : 10.1046/j.1365-2958.2002.03072.x

A. Lankowski and E. Hohmann, Application of a New Technology to an Old Vector, The Journal of Infectious Diseases, vol.195, issue.8, pp.1203-1214, 2007.
DOI : 10.1086/512618

J. Skoble, J. Beaber, Y. Gao, J. Lovchik, L. Sower et al., Killed but Metabolically Active Bacillus anthracis Vaccines Induce Broad and Protective Immunity against Anthrax, Infection and Immunity, vol.77, issue.4, pp.1649-63, 2009.
DOI : 10.1128/IAI.00530-08

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663168

B. Van-houten, D. Croteau, M. Dellavecchia, H. Wang, and C. Kisker, ???Close-fitting sleeves???: DNA damage recognition by the UvrABC nuclease system, Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol.577, issue.1-2, pp.92-117, 2005.
DOI : 10.1016/j.mrfmmm.2005.03.013

M. Skoberne, A. Yewdall, K. Bahjat, E. Godefroy, P. Lauer et al., KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity, Journal of Clinical Investigation, vol.118, issue.12
DOI : 10.1172/JCI31350DS1

A. Detmer and J. Glenting, Live bacterial vaccines--a review and identification of potential hazards, Microbial Cell Factories, vol.5, issue.1, p.23, 2006.
DOI : 10.1186/1475-2859-5-23

C. Stover, X. Pham, A. Erwin, S. Mizoguchi, P. Warrener et al., Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen, Nature, vol.406, issue.6799, pp.959-64, 2000.

C. Marx and M. Lidstrom, Broad-host-range cre-lox system for antibiotic marker recycling in gram-negative bacteria, BioTechniques, vol.33, issue.5, pp.1062-1069, 2002.

S. Malarkannan, L. Mendoza, and N. Shastri, Generation of antigen-specific, lacZ-inducible Tcell hybrids, Methods Mol. Biol, vol.156, pp.265-72, 2001.

A. Sancar and G. Sancar, DNA Repair Enzymes, Annual Review of Biochemistry, vol.57, issue.1, pp.29-67, 1988.
DOI : 10.1146/annurev.bi.57.070188.000333

I. Gordienko, A specific 3' exonuclease activity of UvrABC. The EMBO Journal, Jan, vol.1517, issue.2, pp.626-659, 1998.

A. Dans-molecular and . Therapy, A safe bacterial microsyringe for in vivo antigen delivery and immunotherapy, 2013.